Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyBL-1020
Identification
- Name
- BL-1020
- Accession Number
- DB05687
- Type
- Small Molecule
- Groups
- Investigational
- Description
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
- Synonyms
- Not Available
- Categories
- UNII
- Not Available
- CAS number
- Not Available
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in schizophrenia and schizoaffective disorders.
- Pharmacodynamics
Extensive preclinical testing of BL-1020 has shown it to have a positive safety and pharmacokinetic profile. BL-1020 reduces dopamine activity while avoiding the side affects associated with unmitigated dopamine blockade. In animal models of schizophrenia, BL-1020 reduces behaviors characteristic of psychosis and causes minimal or no impairment of movement, the most severe side effect of classic antipsychotic drugs. Biochemical testing confirms that BL-1020 works via the mechanism previously established for classic antipsychotics. BL-1020 is structurally and mechanistically distinct from the atypical antipsychotics and is not anticipated to trigger diabetes or elevated cholesterol. Preliminary studies do not reveal toxicity.
- Mechanism of action
In radioligand binding studies, BL-1020 displayed strong interaction with dopamine receptors especially D2L and D2S (Ki of 0.27 nM and 0.17 nM respectively), the serotonin receptor 5-HY2a (Ki 0.25 nM) as well as moderate interaction with the GABAA receptor (Ki 3.29 microK).
Target Actions Organism UD(2) dopamine receptor Not Available Human U5-hydroxytryptamine receptor 2A Not Available Human - Absorption
Orally available.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
BL-1020, after oral administration, crosses the blood brain barrier intact and is metabolized to GABA and perphenazine.
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 5'-Deoxy-5'-Methylthioadenosine The serum concentration of BL-1020 can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine. Experimental Acebutolol BL-1020 may increase the hypotensive activities of Acebutolol. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when BL-1020 is combined with Alaproclate. Experimental Alfentanil BL-1020 may increase the hypotensive activities of Alfentanil. Approved, Illicit Almasilate Almasilate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Aloglutamol Aloglutamol can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Alphacetylmethadol BL-1020 may increase the hypotensive activities of Alphacetylmethadol. Experimental, Illicit Alphaprodine BL-1020 may increase the hypotensive activities of Alphaprodine. Illicit Alprenolol BL-1020 may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Aluminium Aluminium can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Amikacin The risk or severity of adverse effects can be increased when BL-1020 is combined with Amikacin. Approved, Investigational, Vet Approved Amodiaquine The serum concentration of BL-1020 can be increased when it is combined with Amodiaquine. Approved, Investigational Amoxapine The risk or severity of adverse effects can be increased when BL-1020 is combined with Amoxapine. Approved Arotinolol BL-1020 may increase the hypotensive activities of Arotinolol. Investigational Artemether The serum concentration of BL-1020 can be increased when it is combined with Artemether. Approved Artemisinin The serum concentration of BL-1020 can be increased when it is combined with Artemisinin. Investigational Artemotil The serum concentration of BL-1020 can be increased when it is combined with Artemotil. Approved Artenimol The serum concentration of BL-1020 can be increased when it is combined with Artenimol. Approved, Investigational Artesunate The serum concentration of BL-1020 can be increased when it is combined with Artesunate. Approved, Investigational Asenapine BL-1020 may increase the hypotensive activities of Asenapine. Approved Atenolol BL-1020 may increase the hypotensive activities of Atenolol. Approved Atovaquone The serum concentration of BL-1020 can be increased when it is combined with Atovaquone. Approved Befunolol BL-1020 may increase the hypotensive activities of Befunolol. Experimental Benzphetamine BL-1020 may decrease the stimulatory activities of Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with BL-1020. Approved Betaxolol BL-1020 may increase the hypotensive activities of Betaxolol. Approved, Investigational Bevantolol BL-1020 may increase the hypotensive activities of Bevantolol. Approved Bezitramide BL-1020 may increase the hypotensive activities of Bezitramide. Experimental, Illicit, Withdrawn Bismuth subcitrate potassium Bismuth Subcitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bisoprolol BL-1020 may increase the hypotensive activities of Bisoprolol. Approved Bopindolol BL-1020 may increase the hypotensive activities of Bopindolol. Approved Botulinum Toxin Type B The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with BL-1020. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with BL-1020. Approved Bucindolol BL-1020 may increase the hypotensive activities of Bucindolol. Investigational Bufuralol BL-1020 may increase the hypotensive activities of Bufuralol. Experimental, Investigational Bupranolol BL-1020 may increase the hypotensive activities of Bupranolol. Approved Buprenorphine BL-1020 may increase the hypotensive activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with BL-1020. Approved Butorphanol BL-1020 may increase the hypotensive activities of Butorphanol. Approved, Illicit, Vet Approved Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium silicate Calcium silicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with BL-1020. Approved, Investigational Carfentanil BL-1020 may increase the hypotensive activities of Carfentanil. Illicit, Investigational, Vet Approved Carteolol BL-1020 may increase the hypotensive activities of Carteolol. Approved Carvedilol The serum concentration of Carvedilol can be increased when it is combined with BL-1020. Approved, Investigational Celiprolol BL-1020 may increase the hypotensive activities of Celiprolol. Approved, Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with BL-1020. Approved Chloroquine The serum concentration of BL-1020 can be increased when it is combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with BL-1020. Approved Chlorproguanil The serum concentration of BL-1020 can be increased when it is combined with Chlorproguanil. Investigational Citalopram The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with BL-1020. Approved, Investigational Clindamycin The risk or severity of adverse effects can be increased when BL-1020 is combined with Clindamycin. Approved, Vet Approved Clomipramine The risk or severity of adverse effects can be increased when BL-1020 is combined with Clomipramine. Approved, Investigational, Vet Approved Cloranolol BL-1020 may increase the hypotensive activities of Cloranolol. Experimental Codeine The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Codeine. Approved, Illicit Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with BL-1020. Approved Cycloguanil embonate The serum concentration of BL-1020 can be increased when it is combined with Cycloguanil embonate. Experimental Cyclosporine The risk or severity of adverse effects can be increased when BL-1020 is combined with Cyclosporine. Approved, Investigational, Vet Approved Dapoxetine The risk or severity of adverse effects can be increased when BL-1020 is combined with Dapoxetine. Investigational Dapsone The serum concentration of BL-1020 can be increased when it is combined with Dapsone. Approved, Investigational Desipramine BL-1020 may increase the hypotensive activities of Desipramine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when BL-1020 is combined with Desvenlafaxine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with BL-1020. Approved Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with BL-1020. Approved Dextromoramide BL-1020 may increase the hypotensive activities of Dextromoramide. Experimental, Illicit Dextropropoxyphene BL-1020 may increase the hypotensive activities of Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine BL-1020 may increase the hypotensive activities of Dezocine. Approved, Investigational Diethylpropion BL-1020 may decrease the stimulatory activities of Diethylpropion. Approved, Illicit Dihydrocodeine BL-1020 may increase the hypotensive activities of Dihydrocodeine. Approved, Illicit Dihydroetorphine BL-1020 may increase the hypotensive activities of Dihydroetorphine. Experimental, Illicit Dihydromorphine BL-1020 may increase the hypotensive activities of Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with BL-1020. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with BL-1020. Approved, Investigational Diphenoxylate BL-1020 may increase the hypotensive activities of Diphenoxylate. Approved, Illicit Dotarizine The risk or severity of adverse effects can be increased when BL-1020 is combined with Dotarizine. Investigational Doxycycline The serum concentration of BL-1020 can be increased when it is combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of BL-1020. Approved, Vet Approved DPDPE BL-1020 may increase the hypotensive activities of DPDPE. Experimental Epanolol BL-1020 may increase the hypotensive activities of Epanolol. Experimental Eperisone The risk or severity of adverse effects can be increased when Eperisone is combined with BL-1020. Approved, Investigational Esatenolol BL-1020 may increase the hypotensive activities of Esatenolol. Experimental Escitalopram The risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram. Approved, Investigational Esmolol BL-1020 may increase the hypotensive activities of Esmolol. Approved Ethanol BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with BL-1020. Approved Ethylmorphine BL-1020 may increase the hypotensive activities of Ethylmorphine. Approved, Illicit Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with BL-1020. Approved Etorphine BL-1020 may increase the hypotensive activities of Etorphine. Illicit, Vet Approved Fenfluramine The risk or severity of adverse effects can be increased when BL-1020 is combined with Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fentanyl The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with BL-1020. Approved Fluoxetine The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine. Approved, Vet Approved Fluspirilene The risk or severity of adverse effects can be increased when Fluspirilene is combined with BL-1020. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with BL-1020. Approved Fluvoxamine The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluvoxamine. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with BL-1020. Approved, Investigational Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with BL-1020. Approved, Investigational Halofantrine The serum concentration of BL-1020 can be increased when it is combined with Halofantrine. Approved Heroin BL-1020 may increase the hypotensive activities of Heroin. Approved, Illicit, Investigational Hydrocodone BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone BL-1020 may increase the hypotensive activities of Hydromorphone. Approved, Illicit Hydrotalcite Hydrotalcite can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Hydroxychloroquine The serum concentration of BL-1020 can be increased when it is combined with Hydroxychloroquine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of BL-1020. Approved Indalpine The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine. Investigational, Withdrawn Indenolol BL-1020 may increase the hypotensive activities of Indenolol. Withdrawn Ketobemidone BL-1020 may increase the hypotensive activities of Ketobemidone. Approved, Investigational Labetalol The serum concentration of Labetalol can be increased when it is combined with BL-1020. Approved Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with BL-1020. Approved, Investigational Landiolol BL-1020 may increase the hypotensive activities of Landiolol. Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with BL-1020. Approved, Investigational Levobetaxolol BL-1020 may increase the hypotensive activities of Levobetaxolol. Approved, Investigational Levobunolol BL-1020 may increase the hypotensive activities of Levobunolol. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with BL-1020. Approved Levomethadyl Acetate BL-1020 may increase the hypotensive activities of Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when BL-1020 is combined with Levomilnacipran. Approved, Investigational Levorphanol BL-1020 may increase the hypotensive activities of Levorphanol. Approved Lofentanil BL-1020 may increase the hypotensive activities of Lofentanil. Illicit Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with BL-1020. Approved, Investigational Lumefantrine The serum concentration of BL-1020 can be increased when it is combined with Lumefantrine. Approved Magaldrate Magaldrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when BL-1020 is combined with Magnesium citrate. Approved Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium silicate Magnesium silicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate The therapeutic efficacy of BL-1020 can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with BL-1020. Approved Mefloquine The serum concentration of BL-1020 can be increased when it is combined with Mefloquine. Approved, Investigational Mepindolol BL-1020 may increase the hypotensive activities of Mepindolol. Experimental Meptazinol BL-1020 may increase the hypotensive activities of Meptazinol. Experimental Methadone BL-1020 may increase the hypotensive activities of Methadone. Approved Methadyl Acetate BL-1020 may increase the hypotensive activities of Methadyl Acetate. Approved, Illicit Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with BL-1020. Approved Methylphenidate The risk or severity of adverse effects can be increased when BL-1020 is combined with Methylphenidate. Approved, Investigational Metipranolol BL-1020 may increase the hypotensive activities of Metipranolol. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with BL-1020. Approved, Investigational Metoprolol The serum concentration of Metoprolol can be increased when it is combined with BL-1020. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when BL-1020 is combined with Milnacipran. Approved, Investigational Mizoribine The serum concentration of BL-1020 can be increased when it is combined with Mizoribine. Investigational Morphine BL-1020 may increase the hypotensive activities of Morphine. Approved, Investigational Nadolol BL-1020 may increase the hypotensive activities of Nadolol. Approved Nalbuphine BL-1020 may increase the hypotensive activities of Nalbuphine. Approved Nebivolol BL-1020 may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when BL-1020 is combined with Nefazodone. Approved, Withdrawn Neomycin The risk or severity of adverse effects can be increased when BL-1020 is combined with Neomycin. Approved, Vet Approved Nicomorphine BL-1020 may increase the hypotensive activities of Nicomorphine. Experimental Normethadone BL-1020 may increase the hypotensive activities of Normethadone. Approved, Illicit Olanzapine The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine. Approved, Investigational Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with BL-1020. Approved Opium BL-1020 may increase the hypotensive activities of Opium. Approved, Illicit Oxprenolol BL-1020 may increase the hypotensive activities of Oxprenolol. Approved Oxycodone The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Oxymorphone. Approved, Investigational, Vet Approved Paromomycin The risk or severity of adverse effects can be increased when BL-1020 is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine. Approved, Investigational Penbutolol BL-1020 may increase the hypotensive activities of Penbutolol. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Penfluridol is combined with BL-1020. Experimental Pentazocine BL-1020 may increase the hypotensive activities of Pentazocine. Approved, Vet Approved Pethidine BL-1020 may increase the hypotensive activities of Pethidine. Approved Phenazocine BL-1020 may increase the hypotensive activities of Phenazocine. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with BL-1020. Approved, Investigational Phenoperidine BL-1020 may increase the hypotensive activities of Phenoperidine. Experimental Pindolol BL-1020 may increase the hypotensive activities of Pindolol. Approved, Investigational Piperaquine The serum concentration of BL-1020 can be increased when it is combined with Piperaquine. Approved, Investigational Piritramide BL-1020 may increase the hypotensive activities of Piritramide. Approved, Investigational Platelet Activating Factor BL-1020 may increase the hypotensive activities of Platelet Activating Factor. Experimental Polymyxin B Sulfate The risk or severity of adverse effects can be increased when BL-1020 is combined with Polymyxin B Sulfate. Approved, Vet Approved Practolol BL-1020 may increase the hypotensive activities of Practolol. Approved Pramipexole BL-1020 may increase the sedative activities of Pramipexole. Approved, Investigational Pregabalin The therapeutic efficacy of BL-1020 can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Primaquine The serum concentration of BL-1020 can be increased when it is combined with Primaquine. Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with BL-1020. Approved, Vet Approved Proguanil The serum concentration of BL-1020 can be increased when it is combined with Proguanil. Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with BL-1020. Approved, Investigational Propafenone The serum concentration of Propafenone can be increased when it is combined with BL-1020. Approved Propranolol The serum concentration of Propranolol can be increased when it is combined with BL-1020. Approved, Investigational Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with BL-1020. Approved Pyrantel The risk or severity of adverse effects can be increased when Pyrantel is combined with BL-1020. Approved, Vet Approved Pyrimethamine The serum concentration of BL-1020 can be increased when it is combined with Pyrimethamine. Approved, Investigational, Vet Approved Pyronaridine The serum concentration of BL-1020 can be increased when it is combined with Pyronaridine. Investigational Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with BL-1020. Approved Quinacrine The serum concentration of BL-1020 can be increased when it is combined with Quinacrine. Approved, Investigational Quinidine The serum concentration of BL-1020 can be increased when it is combined with Quinidine. Approved, Investigational Quinine The serum concentration of BL-1020 can be increased when it is combined with Quinine. Approved Radicicol The serum concentration of BL-1020 can be increased when it is combined with Radicicol. Experimental Remifentanil BL-1020 may increase the hypotensive activities of Remifentanil. Approved Rizatriptan The risk or severity of adverse effects can be increased when Rizatriptan is combined with BL-1020. Approved Ropinirole BL-1020 may increase the sedative activities of Ropinirole. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with BL-1020. Approved, Investigational Sertraline The risk or severity of adverse effects can be increased when BL-1020 is combined with Sertraline. Approved Sinefungin The serum concentration of BL-1020 can be increased when it is combined with Sinefungin. Experimental Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sotalol BL-1020 may increase the hypotensive activities of Sotalol. Approved Sufentanil BL-1020 may increase the hypotensive activities of Sufentanil. Approved, Investigational Sulfadoxine The serum concentration of BL-1020 can be increased when it is combined with Sulfadoxine. Approved, Investigational Sulfametopyrazine The serum concentration of BL-1020 can be increased when it is combined with Sulfametopyrazine. Approved, Withdrawn Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with BL-1020. Approved, Investigational Tafenoquine The serum concentration of BL-1020 can be increased when it is combined with Tafenoquine. Approved, Investigational Talinolol BL-1020 may increase the hypotensive activities of Talinolol. Investigational Tapentadol BL-1020 may increase the hypotensive activities of Tapentadol. Approved Terbutaline BL-1020 may increase the hypotensive activities of Terbutaline. Approved Tertatolol BL-1020 may increase the hypotensive activities of Tertatolol. Experimental Tetracycline The risk or severity of adverse effects can be increased when BL-1020 is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with BL-1020. Investigational Tetrandrine The risk or severity of QTc prolongation can be increased when Tetrandrine is combined with BL-1020. Experimental Thiopental The risk or severity of adverse effects can be increased when BL-1020 is combined with Thiopental. Approved, Vet Approved Tilidine BL-1020 may increase the hypotensive activities of Tilidine. Experimental Timolol BL-1020 may increase the hypotensive activities of Timolol. Approved Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with BL-1020. Approved Tramadol The risk or severity of hypotension and central nervous system depression can be increased when BL-1020 is combined with Tramadol. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone. Approved, Investigational Trimethadione The risk or severity of adverse effects can be increased when Trimethadione is combined with BL-1020. Approved Trimethoprim The serum concentration of BL-1020 can be increased when it is combined with Trimethoprim. Approved, Vet Approved Tromethamine Tromethamine can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with BL-1020. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when BL-1020 is combined with Vancomycin. Approved Vecuronium The risk or severity of adverse effects can be increased when Vecuronium is combined with BL-1020. Approved Venlafaxine The risk or severity of adverse effects can be increased when BL-1020 is combined with Venlafaxine. Approved Vilazodone The risk or severity of adverse effects can be increased when BL-1020 is combined with Vilazodone. Approved Vinpocetine The risk or severity of adverse effects can be increased when Vinpocetine is combined with BL-1020. Investigational Vortioxetine The risk or severity of adverse effects can be increased when BL-1020 is combined with Vortioxetine. Approved, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with BL-1020. Approved Zimelidine The risk or severity of adverse effects can be increased when BL-1020 is combined with Zimelidine. Withdrawn Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with BL-1020. Approved, Investigational Zolpidem BL-1020 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with BL-1020. Approved, Investigational - Food Interactions
- Not Available
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Schizoaffective Disorders / Schizophrenic Disorders 1 2 Completed Treatment Schizophrenic Disorders 1 2, 3 Terminated Treatment Cognitive Effect on Schizophrenic Patients / Schizophrenic Disorders 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Potassium channel regulator activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- DRD2
- Uniprot ID
- P14416
- Uniprot Name
- D(2) dopamine receptor
- Molecular Weight
- 50618.91 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
- Gene Name
- HTR2A
- Uniprot ID
- P28223
- Uniprot Name
- 5-hydroxytryptamine receptor 2A
- Molecular Weight
- 52602.58 Da
Drug created on November 18, 2007 11:27 / Updated on August 02, 2018 05:32